Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06573138
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-16
Brief Title:
Selinexor Anti-PD-1 Antibody Plus Golidocitinib in RR NKTCL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Efficacy and Safety of Selinexor Anti-PD-1 Antibody Plus Golidocitinib in the Treatment of Relapsed or Refractory Natural Killer T-cell Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multicenter prospective trial to evaluate the efficacy and safety of Selinexor anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer T-cell lymphoma
Detailed Description:
This study aims to evaluate the efficacy and safety of Selinexor anti-PD-1 antibody plus Golidocitinib in relapsed or refractory NKTCL and find the optimal treatment regimen for patients with relapsed refractory NKTCL
Patients receive 3 cycles of Selinexor anti-PD-1 antibody plus Golidocitinib and then PET evaluation
Patients receive 3 cycles of Selinexor anti-PD-1 antibody plus Golidocitinib and then PET evaluation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None